Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy with a five-year survival rate of less than 10%. The treatment options for patients with pancreatic cancer are limited to surgery, radiation, and chemotherapies, so demand is high for safer and more-efficacious drugs. In the first line, Folfirinox and Celgene’s Abraxane with gemcitabine therapy have emerged as alternative treatment strategies, while in the second line Merrimack’s Onivyde appears to be a new standard of care. These therapies show only modest survival benefits, with an overall survival of less than one year. Although current treatment is dominated by chemotherapies, upcoming targeted therapies including Halozyme Therapeutics’ PEGPH20 and AstraZeneca / Merck’s Lynparza are expected to be better-tolerated treatment options.

Questions answered:

  • What is the size of the U.S., EU5, and Japanese pancreatic cancer and PNETs drug-treatable patient population? How will drug-treatment rates change over our ten-year forecast period?
  • How are patients with pancreatic cancer and PNETs treated in the markets under study? What are interviewed experts’ insights on current treatment options?
  • What clinical needs remain unfulfilled, and which needs will be addressed by the end of our ten-year forecast period?
  • What are the key emerging therapies in development for pancreatic cancer and PNETs? What sales / uptake could these therapies secure in the pancreatic cancer market? What does the early-phase pipeline look like?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • August 2019
      • June 2019
      • December 2017
      • August 2017
    • Executive Summary
      • Key Findings
    • Market Outlook
      • Key Findings
        • Expert Insight
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Pancreatic Cancer?
        • What Factors Are Constraining the Market for Pancreatic Cancer?
      • Segment-Specific Trends
        • Resectable (Stage I-IIB)
        • Unresectable (Stage III), First Line
        • Metastatic, First Line
        • Metastatic, Second Line
    • Forecast
    • Etiology and Pathophysiology
      • Key Findings
        • Expert Insight
      • Disease Overview
        • Etiology
        • Disease Pathophysiology
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Pancreatic Cancer
        • Recurrent Incident Cases of Pancreatic Cancer
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment Overview
      • Key Findings
        • Expert Insight
      • Treatment Goals
        • Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Mechanism of Action of Key Current Drugs or Drug Classes Used for Pancreatic Cancer
        • Current Treatments Used for Pancreatic Cancer
        • Therapies for the Treatment of Pancreatic Adenocarcinoma
        • Therapies for the Treatment of Pancreatic Neuroendocrine Tumors
      • Medical Practice
        • Pancreatic Cancer: Resectable (Stage I-IIB)
        • Pancreatic Cancer: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
        • Pancreatic Cancer: Metastatic, Second-Line
        • Pancreatic Neuroendocrine Tumors: Resectable (Stage I-II)
        • Pancreatic Neuroendocrine Tumors: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
        • Pancreatic Neuroendocrine Tumors: Metastatic, Second-Line
        • Treatment Guidelines for Pancreatic Adenocarcinoma
        • Treatment Guidelines for Pancreatic Neuroendocrine Tumors
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Key Findings
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Pancreatic Cancer
        • Future Attainment of Unmet Needs in Pancreatic Cancer
    • Emerging Therapies Overview
      • Key Findings
        • Expert Insight
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Pancreatic Cancer
        • Novel Biomarkers Under Evaluation for Better Stratification of Patients with Pancreatic Adenocarcinoma
        • Alkylating Agents
        • Antimetabolites
        • Bruton's Tyrosine Kinase Inhibitors
        • Cancer Stemness Pathway Inhibitors
        • C-KIT Tyrosine Kinase Inhibitors
        • Dendritic Cell Cancer Vaccines
        • PARP Inhibitors
        • Pegylated Hyaluronidase
        • Pegylated Interleukin-10
        • Platinum Agents
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Pancreatic Cancer
        • Immune Checkpoint Inhibitors
      • Key Discontinuations and Failures in Pancreatic Cancer
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Pancreatic Cancer Bibliography

Author(s): Ananya Sadhu, Ph.D

Ananya Sadhu, is an analyst with the oncology team at Decision Resources Group with expertise in multiple oncology indications including pancreatic cancer. Prior to joining Decision Resources Group, Dr. Ananya Sadhu was a postdoctoral fellow at National Centre of Biological Sciences, Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. Ananya holds a in Molecular Biology from National Institute of Immunology, New Delhi. She also worked as a Scientific Officer with Arvind Remedies Ltd., a pharmaceutical company, where she coordinated various stages of non-clinical / clinical research activities for drug development of a patented polyherbal formulation.


Related Reports

Pancreatic Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key  pancreatic cancer&nb...

View Details

Pancreatic Cancer | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevale...

View Details

Pancreatic Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU) Locally Advanced or Metastatic Adenocarcinoma

MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of...

View Details